Filtered By:
Specialty: Drugs & Pharmacology
Condition: Bleeding
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 688 results found since Jan 2013.
Should coronary catheter laboratories be used in the treatment of ischemic stroke? Endovascular treatment in acute ischemic stroke performed by interventional cardiologists
CONCLUSIONS: ET in AIS can be performed safely with high success rates by trained interventional cardiologists within the stroke team. Until the number of stroke centers is sufficient, endovascular treatment of AIS can be supported by experienced interventional cardiologists.PMID:35363332 | DOI:10.26355/eurrev_202203_28329
Source: European Review for Medical and Pharmacological Sciences - April 1, 2022 Category: Drugs & Pharmacology Authors: I Kocayigit H Kilic B A Acar T Acar Y G Aras Y Can H A Ery ılmaz S Boncuk R Akdemir Source Type: research
Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
Acta Pharmacol Sin. 2022 Mar 30. doi: 10.1038/s41401-022-00892-9. Online ahead of print.ABSTRACTRivaroxaban, a direct factor Xa inhibitor, is widely used for stroke prevention in patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to conduct a population pharmacokinetic-pharmacodynamic (PK-PD) analysis of rivaroxaban in Chinese patients with NVAF to assess ethnic differences and provide model-based precision dosing. A total of 256 rivaroxaban plasma concentrations and 244 prothrombin time (PT) measurements were obtained from 195 Chinese NVAF patients from a prospective clinical trial. The popul...
Source: Acta Pharmacologica Sinica - March 31, 2022 Category: Drugs & Pharmacology Authors: Xiao-Qin Liu Yu-Fei Zhang Hong-Yan Ding Ming-Ming Yan Zheng Jiao Ming-Kang Zhong Chun-Lai Ma Source Type: research
Cinnamon and Aspirin for Mild Ischemic Stroke or Transient Ischemic Attack: A Pilot Trial
Clin Ther. 2022 Mar 25:S0149-2918(22)00082-0. doi: 10.1016/j.clinthera.2022.02.012. Online ahead of print.ABSTRACTPURPOSE: Cinnamon can reduce levels of blood lipids, blood glucose, and inflammation, which are risk factors for ischemic stroke and transient ischemic attack (TIA).The goal of this study was to observe the safety and efficacy of aspirin combined with cinnamon in the treatment of patients with mild stroke or TIA.METHODS: This pilot study included patients with mild stroke or TIA treated at Guangdong Provincial People's Hospital-Nanhai Hospital between January 2014 and December 2016. The primary end point was re...
Source: Clinical Therapeutics - March 29, 2022 Category: Drugs & Pharmacology Authors: Lei Zhang Zhanhui Li Yuewen Wu Yanming Fan Zhicong He Peng He Jingxing Liang Source Type: research
The outcomes of reperfusion therapy with streptokinase versus tenecteplase in ST-elevation myocardial infarction (STEMI): a propensity-matched retrospective analysis in an Asian population
Conclusion Streptokinase and tenecteplase are fibrinolytic agents with similar efficacy and safety in STEMI reperfusion therapy in our Asian population.
Source: International Journal of Clinical Pharmacy - March 3, 2022 Category: Drugs & Pharmacology Source Type: research
Non-Vitamin K Oral Anticoagulant After Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis
Conclusion: For patients with an indication for oral anticoagulation after TAVR, NOACs seem to be associated with noninferior outcomes compared with VKA therapy. However, for patients without an indication for oral anticoagulation, NOACs appear to be associated with a higher risk of all-cause death as compared with antiplatelet treatment.Systematic Review Registration:https://clinicaltrials.gov/, identifier CRD42020155122.
Source: Frontiers in Pharmacology - February 11, 2022 Category: Drugs & Pharmacology Source Type: research
Influence of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation
Conclusion: In our study, we determined that carriers of CYP4F2 gene polymorphisms C(Val433Met)T, PEAR1 rs41273215 C#x3e;T (CT+TT) were associated with lower safety of antithrombotic therapy in patients with ACS and AF. And, the B4GALT2 rs1061781 gene polymorphism was associated with a greater risk of insufficient efficacy of the therapy. The data obtained in our study may improve the understanding of the effect of less studied genetic markers on the efficacy and safety of antithrombotic therapy in patients with ACS and AF.Pharmacology
Source: Pharmacology - January 24, 2022 Category: Drugs & Pharmacology Source Type: research
